ETT A.I CyberSecurity Scoring
03/01/2026
Access Monitoring Plan
Access Monitoring Plan
No incidents recorded for Emory Technology Transfer in 2026.
No incidents recorded for Emory Technology Transfer in 2026.
No incidents recorded for Emory Technology Transfer in 2026.
NIH is the only agency of its kind. We impact the health of the country and the world through unique and innovative medical research. Did you know that NIH is the largest public funder of biomedical research in the world, investing more than $32 billion a year to enhance life, and reduce illness and disability? NIH funded research has led to breakthroughs and new treatments, helping people live longer, healthier lives, and building the research foundation that drives discovery. Whether you are graduating with a bachelor's degree, working on your doctoral degree, entering the workforce for the first time, or changing careers, NIH offers a place for you to start and plenty of room to grow your career. When you join us, you’re not just advancing your career — you’re driving the health of our country forward. Official LinkedIn Account of the NIH. Privacy policy: http://go.usa.gov/x9svN Comment policy: https://bit.ly/3G6xq94 Engagement ≠ endorsement
Since our foundation in Dublin, Ireland in 1990, our mission has been to help our clients to accelerate the development of drugs and devices that save lives and improve quality of life. We do this by delivering best in class information, solutions and performance, with an unyielding focus on quality at all times. We offer a full range of consulting, development and commercialisation services from a global network of offices in 53 countries. We focus our innovation on the factors that are critical to our clients – reducing time to market, reducing cost, and increasing quality – and our global team of experts has extensive experience in a broad range of therapeutic areas.
Amgen harnesses the best of biology and technology to fight the world’s toughest diseases, and make people’s lives easier, fuller and longer. We helped establish the biotechnology industry, and we remain on the cutting-edge of innovation, using technology and human genetic data to push beyond what’s known today. Our investment in research and development has yielded a robust pipeline that builds on our existing portfolio of medicines to treat cancer, heart disease, osteoporosis, inflammatory diseases and rare diseases. Amgen is one of 30 companies comprising the Dow Jones Industrial Average®, and part of the Nasdaq-100 Index®. In 2024, Amgen was named one of the “World’s Most Innovative Companies” by Fast Company and one of “America’s Best Large Employers” by Forbes. For more information, visit Amgen.com and follow us on X, LinkedIn, Instagram, TikTok, YouTube and Threads. 🔗 Community Guidelines: https://wwwext.amgen.com/community-guidelines 🔗Global Privacy Statement Directory: www.amgen.com/dp Special Advisory: Please be cautious of scam recruitment offers claiming to be from Amgen. Such scams may come from various sources, including fake websites and/or unsolicited emails and seek to obtain personal data or payment from victims by offering jobs that do not exist. Please be advised that Amgen would never ask for payment to progress a job application. When in doubt, please check to see if the position in question is posted on this website before applying. Additionally, please report any suspicious recruiting activity to https://complaint.ic3.gov/ and thank you for your assistance.
Syneos Health® is a leading fully integrated biopharmaceutical solutions organization built to accelerate customer success. We translate unique clinical, medical affairs and commercial insights into outcomes to address modern market realities. We bring together a talented team of professionals with a deep understanding of patient and physician behaviors and market dynamics. Together we share insights, use the latest technologies and apply advanced business practices to speed our customers’ delivery of important therapies to patients. Syneos Health supports a diverse, equitable and inclusive culture that cares for colleagues, customers, patients, communities and the environment.
A family-owned company, bioMérieux has grown to become a world leader in the field of in vitro diagnostics. Our entrepreneurial adventure, begun over a century ago, is driven by an unrelenting commitment to improve public health worldwide. Since 1963, we've been paving the way in the field of in vitro diagnostics and have contributed greatly to improving public health and making the world a healthier place. The solutions that our teams imagine, develop and manufacture are key to enable healthcare professionals and industry players to make confident decisions to improve patient outcome and ensure consumer safety.
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. Thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Roche has been recognised as the Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry ten years in a row by the Dow Jones Sustainability Indices (DJSI). For more information, please visit https://careers.roche.com Read our community guidelines here: https://www.roche.com/some-guidelines.htm #Roche #Biotechnology #Pharmaceuticals #Diagnostics #Healthcare #PersonalisedHealthcare #GreatPlaceToWork #Innovation
At Charles River, we are guided by our strong purpose—to create healthier lives—which centers around the patients who rely on the therapeutics we help to develop, the animals in our care, to our planet, and to the passionate and skilled people who are at the heart of our organization and make it all possible. #DrugDiscovery #Biotech #Biotechnology #Pharmaceuticals #CRL
About Genentech We're passionate about finding solutions for people facing the world's most difficult-to-treat conditions. That is why we use cutting-edge science to create and deliver innovative medicines around the globe. To us, science is personal. Making a difference in the lives of millions starts when you make a change in yours. If you’d like to join our team, view our openings at gene.com/careers. Our patient resource center is dedicated to getting patients and caregivers to the right resources. You can reach them at 1 (877) GENENTECH (436-3683) Monday-Friday, 6am-5pm PST or [email protected]. Community Guidelines: 1. We want to foster positive conversation around the issues we are passionate about. To that end, we remove profanity, content that contains threatening language, content that is aimed at private individuals, personal information, and repeated unwanted messages. 2. Don’t mention any medicines by name — ours or anyone else’s. Because of the fair balance rules governing our industry, we cannot post any comments that reference any pharmaceutical brand, product, or service. Please do not mention any specific medicines by name, or include any links to third party sites in your comments. 3. This isn’t the place to report or discuss side effects. This site is not intended as a forum for reporting side effects experienced while taking a Genentech product. Instead, you should report any side effects to Genentech Drug Safety at 1-888-835-2555. You can also report side effects of any prescription product directly to the FDA at 1-800-FDA-1088 or by visiting www.FDA.gov/medwatch. 4. Don’t pitch your product or service. Please don't use our page as a place to promote your product or pitch your services. Please also avoid posting links to external sites. We reserve the right to remove any posts that are deemed promotional.
About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com.
Latest updates, reports, and threat intel affecting the global network.
Emory's Office of Technology Transfer recently held its 18th Annual Celebration of Technology and Innovation, where it honored outstanding...
KU Innovation Park — the business incubator and technology center on KU's West Campus — has hired a former top executive of the University of...
In Zephyr's userspace dynamic-objects subsystem, thread_idx_alloc() in kernel/userspace/userspace.c allocated a new thread permission index from the global _thread_idx_map[] bitmap without holding lists_lock. On SMP systems, two user-mode threads invoking the k_object_alloc(K_OBJ_THREAD) syscall concurrently can both observe the same low free bit, perform the same non-atomic RMW to clear it, and return the identical tidx. The two newly created K_OBJ_THREAD objects are then assigned the same thread_id, so the two user threads alias a single bit position in every kernel object's perms[] bitfield: any subsequent grant of access on a kernel object to one thread is implicitly a grant to the other, defeating userspace ACL isolation. A secondary lost-update window between the unlocked &=~BIT() in alloc and the locked |= BIT() in thread_idx_free() can also leak entries from the thread-index pool. The defect is reachable from any user-mode thread via the unrestricted __syscall k_object_alloc and is gated on CONFIG_USERSPACE, CONFIG_DYNAMIC_OBJECTS, and CONFIG_SMP. The flaw was introduced when the per-thread permission index was added in 2018 and is present in every release up to and including v4.4.0. Fixed by holding lists_lock across the bitmap RMW and the permissions clear (and inlining the obj_list traversal that previously took the lock itself).
OpenRemote before 1.26.2 contains an authentication bypass vulnerability in the console registration API that allows unauthenticated attackers to update existing console assets by supplying a known asset identifier. Attackers can overwrite push notification tokens and console metadata without authentication or ownership validation, redirecting notifications or denying delivery to legitimate consoles.
SiYuan before v3.7.2 contains a missing authorization vulnerability in the POST /mcp kernel endpoint, which is gated only by a general auth check (model.CheckAuth) with no admin-role or read-only enforcement. This exposes 31 MCP tools, including a file tool with list/read/write/delete/rename/copy actions across the entire workspace. When the Publish server is enabled in anonymous mode (Conf.Publish.Enable=true and Conf.Publish.Auth.Enable=false), the Publish reverse proxy attaches an anonymous RoleReader JWT to proxied requests, allowing a remote unauthenticated attacker to reach /mcp. The attacker can read conf/conf.json to extract accessAuthCode, api.token, and cookieKey in plaintext, write arbitrary files in the workspace, and plant a plugin into data/plugins/ that executes with nodeIntegration:true and no contextIsolation on the next desktop launch, leading to administrator takeover.
ImageMagick before 7.1.2-27 contains a memory leak vulnerability in the magick command-line interface when invalid options are provided. Attackers can trigger memory exhaustion by repeatedly supplying malformed command-line arguments to consume system resources.
In the Linux kernel, the following vulnerability has been resolved: crypto: qat - remove unused character device and IOCTLs The QAT driver exposes a character device (qat_adf_ctl) with IOCTLs for device configuration, start, stop, status query and enumeration. These IOCTLs are not part of any public uAPI header and have no known in-tree or out-of-tree users. Device lifecycle is already managed via sysfs. The ioctl interface also increases the attack surface and is the subject of a number of bug reports. Remove the character device, the IOCTL definitions, and the related data structures (adf_dev_status_info, adf_user_cfg_key_val, adf_user_cfg_section, adf_user_cfg_ctl_data). Drop the now-unused adf_cfg_user.h header and strip adf_ctl_drv.c down to the minimal module_init/module_exit hooks for workqueue, AER, and crypto/compression algorithm registration. Clean up leftover dead code that was only reachable from the removed IOCTL paths: adf_cfg_del_all(), adf_devmgr_verify_id(), adf_devmgr_get_num_dev(), adf_devmgr_get_dev_by_id(), adf_get_vf_real_id() and the unused ADF_CFG macros. Additionally, drop the entry associated to QAT IOCTLs in ioctl-number.rst.
curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'
Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.
Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.